Methylglyoxal:a new therapeutic target for diabetic complications

TANG Yong-jun,DU Jun
DOI: https://doi.org/10.3321/j.issn:1003-3734.2006.18.006
2006-01-01
Abstract:Methylglyoxal (MG) is aα-ketoaldehyde and dicarbonyl formed in cells as a side product of normal glycometabolism.Recent studies have demonstrated that endogenous accumulation of methylglyoxal in the diabetic patients may result in numerous pathogenic processes in vivo,including re- nal dysfunction,cardiovascular diseases,cataract or aging.An experimental approach provided a clue re- garding the interaction of MG with amino acid residues,resulting in a type of advanced glycation end- products(AGEs)from sugar modifications advanced glycation end-product formation.Moreover,methyl- glyoxal induces a crosslink with biological macromolecules(DNA,RNA or proteins),thus expecting se- vere cellular toxicity.This paper presents a comprehensive overview of methylglyoxal research,extending discussion from chemistry to biological implications by reviewing some important characteristics of methyl- glyoxal metabolism and toxicity,and proposing a strategy of treatment of diabetic complications by inhibi- ting methylglyoxal biosynthesis and facilitating methylglyoxalase metabolism.
What problem does this paper attempt to address?